Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001043459 | SCV001207207 | pathogenic | Achondrogenesis, type IB; Atelosteogenesis type II; Multiple epiphyseal dysplasia type 4; Diastrophic dysplasia | 2023-04-23 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. This variant disrupts a region of the SLC26A2 protein in which other variant(s) (p.Ala715Val ) have been determined to be pathogenic (PMID: 11448940, 15294877, 21077204). This suggests that this is a clinically significant region of the protein, and that variants that disrupt it are likely to be disease-causing. ClinVar contains an entry for this variant (Variation ID: 841272). This variant has not been reported in the literature in individuals affected with SLC26A2-related conditions. This variant is present in population databases (rs772515802, gnomAD 0.006%). This sequence change creates a premature translational stop signal (p.Asp673Leufs*2) in the SLC26A2 gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 67 amino acid(s) of the SLC26A2 protein. |
Baylor Genetics | RCV001832414 | SCV004201781 | likely pathogenic | Achondrogenesis, type IB | 2024-03-08 | criteria provided, single submitter | clinical testing | |
Natera, |
RCV001832414 | SCV002081863 | likely pathogenic | Achondrogenesis, type IB | 2021-03-03 | no assertion criteria provided | clinical testing |